Quarterly report pursuant to Section 13 or 15(d)

OTHER RELATED PARTY TRANSACTIONS (Details Narrative)

v3.21.2
OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jun. 15, 2021
Mar. 09, 2021
Apr. 30, 2019
May 31, 2021
Mar. 31, 2021
Feb. 28, 2021
Dec. 31, 2020
Aug. 31, 2020
Apr. 30, 2021
Jul. 31, 2021
Related Party Transaction [Line Items]                    
Common stock, par value (in dollars per share)                   $ 0.0001
IPO [Member]                    
Related Party Transaction [Line Items]                    
Number of shares purchase (in shares) 2,500,000                  
Subsequent Event [Member] | William Horne [Member]                    
Related Party Transaction [Line Items]                    
Number of shares issued for services, value       $ 50,000            
Subsequent Event [Member] | IPO [Member] | Mr Ault [Member]                    
Related Party Transaction [Line Items]                    
Description of conversion       the effectiveness of the IPO, and in consideration for (i) the conversion of 750 shares of the Company’s series A convertible preferred stock beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of Common Stock, (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by Ault Life Sciences Fund, LLC, an entity controlled by Mr. Ault, to December 31, 2023, and (iii) the resignation by Mr. Ault as a director and executive officer of the Company            
Percentage of outstanding common shares       5.00%            
Ault Life Sciences Fund L L C [Member]                    
Related Party Transaction [Line Items]                    
Short-term advances           $ 1,000,000 $ 800,000      
Digital Power Lending [Member] | IPO [Member]                    
Related Party Transaction [Line Items]                    
Number of shares sold (in shares) 2,000,000                  
Securities Purchase Agreement [Member] | Ault Life Sciences Fund L L C [Member]                    
Related Party Transaction [Line Items]                    
Principal amount               $ 50,000    
Number of shares purchase (in shares)     10,000,000              
Interest rate               8.00%    
Common stock, par value (in dollars per share)               $ 1.50    
Securities Purchase Agreement [Member] | Ault Life Sciences Fund L L C [Member] | Warrant [Member]                    
Related Party Transaction [Line Items]                    
Number of shares purchase (in shares)               16,667    
Exercise price (in dollars per share)     $ 3.00         $ 3.00    
Securities Purchase Agreement [Member] | Digital Power Lending [Member]                    
Related Party Transaction [Line Items]                    
Short-term advances                 $ 1,800,000  
Number of shares sold (in shares)         6,666,667          
Number of shares sold         $ 10,000,000          
Description of related party transaction   DPL paid $4 million, less the $1.8 million in advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Global, each as described below, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, DPL purchased an additional (i) 1,333,333 shares of Common Stock upon approval of the IND for Phase Ia clinical trials for a purchase price of $2 million, and (ii) will purchase 2,666,667 shares of the Company’s Common Stock upon the completion of these Phase Ia clinical trials for a purchase price of $4 million.                
Description of milestones         As of the date this Quarterly Report, the first milestones related to FDA approval of IND for Phase Ia clinical trial. The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of July 31, 2021          
Consulting Agreement [Member] | Subsequent Event [Member] | IPO [Member] | Mr Ault [Member]                    
Related Party Transaction [Line Items]                    
Advisory and consulting services fees       $ 50,000